Leap Therapeutics Slashes R&D Spending
Leap Therapeutics (NASDAQ:LPTX), a clinical-stage biotechnology company focused on cancer therapies, released its second quarter 2025 results on August 14, 2025. The company reported a net loss of $(0.40) per share (GAAP), coming in wider than analyst estimates of $(0.29) per share. The main news was the initiation of a strategic alternatives process and a significant reduction in workforce. Research and development expenses (GAAP) fell substantially compared to Q2 2024, but the company missed GAAP earnings expectations despite these cost-cutting efforts. Overall, the quarter highlighted progress in clinical trials but underscored ongoing financial and operational challenges.
Source: Analyst estimates for the quarter provided by FactSet.
Leap Therapeutics is a biotech company developing novel monoclonal antibodies for cancer treatment. Its leading pipeline asset is sirexatamab (DKN-01), a drug targeting DKK1, which is involved in cancer growth and immune system evasion. The company also has FL-501, an antibody targeting GDF-15, in earlier-stage development.
Source Fool.com
